<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041364</url>
  </required_header>
  <id_info>
    <org_study_id>Biomarker fatigue ABC001</org_study_id>
    <nct_id>NCT02041364</nct_id>
  </id_info>
  <brief_title>Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer</brief_title>
  <official_title>Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer: Evaluation of Plasma and Lymphocyte Expression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Medicina do ABC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina do ABC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fatigue is common in cancer patients receiving adjuvant chemotherapy. To further understand&#xD;
      the mechanism of fatigue and search for potential biomarkers, we will conduct a prospective&#xD;
      study with breast cancer patients receiving adjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with breast cancer undergoing adjuvant systemic chemotherapy based on the use of&#xD;
      anthracyclines will be screened before the start of chemotherapy.&#xD;
&#xD;
      Patients whose scores on the brief fatigue inventory (BFI) increase after having received the&#xD;
      first cycle of chemotherapy will be considered as having manifested fatigue. The patients&#xD;
      whose fatigue won't worse following the first cycle of chemotherapy will be used as controls.&#xD;
      We will collect blood samples of both groups before and 21 days after the start of&#xD;
      chemotherapy. We will analyze the following biomarkers: IL2, IL10, TNF and TGFB-1 measured by&#xD;
      amplification reaction; FSH, LH, estradiol, DHEA, DHEAS and cortisol hormones measured by&#xD;
      chemiluminescent enzyme immunometric assay&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Potential biomarkers related to chemotherapy induced fatigue</measure>
    <time_frame>21 days after the start of chemotherapy</time_frame>
    <description>This study examines potential biomarkers of fatigue induced by chemotherapy both in the plasma and mononuclear fraction of the peripheral blood of patients with breast cancer</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Fatigue</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Control: patients without fatigue</arm_group_label>
    <description>Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with fatighe</arm_group_label>
    <description>Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage I, II and III breast cancer undergoing adjuvant systemic chemotherapy&#xD;
        based on the use of anthracyclines will be screened before the start of their treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non metastatic breast cancer;&#xD;
&#xD;
          -  Patients undergoing adjuvant chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypothyroidism;&#xD;
&#xD;
          -  Depression;&#xD;
&#xD;
          -  anemia;&#xD;
&#xD;
          -  heart disease or decompensated hypertension&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe M Cruz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>551134744249</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felipe M Cruz, PhD</last_name>
    <phone>551144362094</phone>
    <email>felipemcruz@yahoo.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cepho-Fmabc</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>09030-310</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Cruz, PhD</last_name>
      <phone>551181388214</phone>
      <email>felipemcruz@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Felipe M Cruz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 18, 2014</study_first_submitted>
  <study_first_submitted_qc>January 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>January 18, 2014</last_update_submitted>
  <last_update_submitted_qc>January 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Medicina do ABC</investigator_affiliation>
    <investigator_full_name>Felipe Melo Cruz</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Fatigue</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

